Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 14, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 3,800,000 ordinary shares.
- Repurchase Price: 1,005.90 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.27% of total voting rights).
- Shares in Issue: 5,438,994,058 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 3,800,000 shares. Consequently, the number of shares held in Treasury has increased to 504,194,158. The filing does not provide comparative data for prior periods regarding share buybacks or capital structure.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,438,994,058) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (504,194,158) and its impact on the total voting rights structure (9.27% held in Treasury).
- Note that the repurchased shares were cancelled, permanently reducing the authorized share count.